| 1. ABBAS, A.K.; LICHTMAN, A.H. & POKER, J.S. - Cellular and molecular immunology, 3.ed., Philadelphia, W.B. Saunders, 1997.2. AHN, S.H.; HAN, K.H.; PARK, J.Y. et al. - Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology, 31: 1371–1373, 2000.3. AIKAWA, T.; KOJIMA, M.; ONISHI, H. et al. - HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J. med. Virol., 49: 274-278, 1996.4. ALMARRI, A. & BATCHELOR, J.R. - HLA and hepatitis B infection. Lancet, 344: 1194-1195, 1994.5. ALRIC, L.; FORT, M.; IZOPET, J. et al. - Genes of the major histocompatibility complex II influence the outcome of hepatitis C virus infection. Gastroenterology, 113: 1675-1681, 1997.6. ANONYMOUS - Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR, 47: 1-39, 1998.7. AWAD, M.R.; EL-GAMEL, A.; HASLETON, P. et al. - Genotypic variation in the transforming growth factor-beta 1 gene: association with transforming growth factor-beta 1 production, fibrotic lung disease and graft fibrosis after lung transplantation. Transplantation, 66: 1014-1020, 1998.8. BAKER, S.J. & REDDY, E.P. - Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene, 12: 1-9, 1996.9. BARRETT, S.; RYAN, E. & CROWE, J. - Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J. Hepatol., 30: 979-983, 1999.10. BATALLER, R.; GINES, P.; GORBIG, M.N.; NICOLAS, J.M.; GARCIA-RAMALLO, E.; ARROYO, V. & RODES J. - Angiotensin II induces contraction and is motogenic for culture human hepatic stellate cells. Antagonization by losartan and modulation by vasodilators [Abstract]. Hepatology, 28 (suppl): 437A, 1998.11. BEDOSSA, P. & PARADIS, V. - Transforming growth factor-beta (TGF-beta): a key-role in liver fibrogenesis. J.Hepat., 22 (suppl. 2): 37-42, 1995.12. BELLAMY, R.; RUWENDE, C.; CORRAH, T. et al. - Variations in the NRAMP 1 gene and susceptibility to tuberculosis in West Africans.New Engl. J. Med., 338: 640-644, 1998.13. BELLAMY, R.; RUWENDE, C.; CORRAH, T.; McADAM, K.P.; THURSZ, M.; WHITTLE, H.C. & HILL, A.V. - Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J. infect. Dis., 179: 721-724, 1999.14. BONKOVSKY, H.L.; BANNER, B.F. & ROTHMAN, A.L. - Iron and chronic viral hepatitis. Hepatology, 25: 759-768, 1997.15. CARRINGTON, M.; MARTI, D.; WADE, J. et al. - Microsatellite markers in complex disease: mapping disease associated regions within in the human major histocompatibility complex. In: GOLDSTEIN, DB. & SCHOTTERER, C. ed. – Microsatellites: evolution and applications. Oxford, Oxford University Press, 1999, p. 225-237.16. CARRINGTON, M.; NELSON, G.W.; MARTIN, M.P. et al. - HLA and HIV-1: heterozygote advantage and B* 35-Cw* 04 disadvantage. Science, 283: 1748-1752, 1999.17. CONGIA, M.; CLEMENT, M.G.; DESSI, C. et al. - HLA class II genes in chronic hepatitis C virus infection and associated immunological disorders. Hepatology, 24: 1338-1341, 1996.18. CRAMP, M.E.; CARUCCI, P.; UNDERHILL, J. et al. - Association between HLA class II genotype and spontaneous clearance of hepatitis B viraemia. J. Hepat., 29: 207-213, 1998.19. DENG, H.; LIU, R.; ELLMEIER, W. et al. - Identification of a major co-receptor for primary isolates of HIV-1. Nature, 381: 661-666, 1996.20. DIB, C.; FAURE, S.; FIZAMES, C. et al. - A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature, 380: 152-154, 1996.21. DOHERTY, P.C. & ZINKERNAGEL, R.M. - Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature, 256: 50-52, 1975.22. DONALDSON, P.T.; DOHERTY, D.G.; HAYLLAR, K.M. et al. – Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology, 13: 701-706, 1991.23. TROWSDALE, J. - Molecular genetics of HLA class I and class II regions. In: BROWNING, M. & McMICHAEL, A. ed. HLA and MHC: genes molecules and function. Oxford, Bios Scientific, 1996, p. 23-37.24. FANNING, L.; KENNY, E.; SHEEHAN, M. et al. - Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology, 29: 904-906, 1999.25. FANNING, L.J.; LEVIS, J.; KENNY-WALSH, E. et al. - Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. Hepatology, 31: 1334-1337, 2000.26. FEDER, J.N.; GNIRKE, A.; THOMAS, W. et al. - A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics, 13: 399-408, 1996.27. FUJISAWA, T.; IKEGAMI, H.; KAWAGUCHI, Y. et al. – Class I HLA is associated with age-at-once of IDDM, while class II HLA confers susceptibility to IDDM. Diabetologia, 38: 1493 – 1495, 1995.28. GIBBONS, G.H.; PRATT, R.E. & DZAU, V.J. - Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor b1 expression determines growth responses to angiotensin II. J. clin. Invest., 90: 456-461, 1992.29. GIORDANO, M.; OEFNER, P.J.; UNDERHILL, P.A. et al. – Identification by denaturing high-performance liquid chromatography of numerous polymorphisms in a candidate region for multiple sclerosis susceptibility. Genomics, 56: 247-253, 1999.30. GUIDOTTI, L.G.; ISHIKAWA, T.; HOBBS, M.V. et al. - Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity, 4: 25-36, 1996.31. HEZODE, C.; CAZENEUVE, C.; COUE, O. et al. - Hemochromatosis Cys 282 Tyr mutation and liver iron overload in patients with chronic active hepatitis C. Hepatology, 27: 306, 1998.32. HIGASHI, Y.; KAMIKAWAJI, N.; SUKO, H. & ANDO, M. - Analysis of HLA alleles in Japanese patients with cirrhosis due to chronic hepatitis C. J. Gastroent. Hepat., 11: 241-246, 1996.33. HOHLER, T.; GERKEN, G.; NOTGHI, A. et al. - MHC class II genes influence the susceptibility to chronic active hepatitis C. J. Hepat., 27: 259-264, 1997.34. HOHLER, T.; GERKEN, G.; NOTGHI, A. et al. - HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J. Hepat., 26: 503-507, 1997.35. HOHLER, T.; KRUGER, A.; GERKEN, G. et al. - Tumor necrosis factor alpha promoter polymorphism at position –238 is associated with chronic active hepatitis C infection. J. med. Virol., 54: 173-177, 1998.36. HOHLER, T.; KRUGER, A.; GERKEN, G. et al. - A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin. exp. Immunol., 111: 579-582, 1998.37. HUE, S.; CACOUB, P.; RENOU, C. et al. - Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J. infect. Dis., 186: 106-109, 2002.38. JIANG, Y.G.; WANG, Y.M.; LIU, T.H. & LIU, J. - Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. Wld J. Gastroent., 9: 2221 – 2225, 200339. KAZEMI-SHIRAZI, L.; DATZ, C.; MAIER-DOBERSBERGER, T. et al. - The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology, 116: 127-134, 1999.40. KENNY-WALSH, E. - Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. New Engl. J. Med., 340: 1228-1233, 1999.41. KNODELL, R.G.; ISHAK, K.G.; BLACK, W.C. et al. - Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1: 431-435, 1981.42. KOZIEL, M.J.; DUDLEY, D.; AFDHAL, N. et al. - HLA class I – restricted cytotoxic T lymphocytes specific for hepatitis C virus – Identification of multiple epitopes and characterization of patterns of cytokine release. J. clin. Invest., 96: 2311-2321, 1995.43. KUZUSHITA, N.; HAYASHI, N.; KATAYAMA, K. et al. - Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J. med. Virol., 48: 1-7, 1996.44. KUZUSHITA, N.; HAYASHI, N.; MORIBE, T. et al. - Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology, 27: 240-244, 1998.45. LEE, W.M. - Hepatitis B virus infection. New Engl. J. Med., 337: 1733-1745, 1997.46. LECHMANN, M.; SCHNEIDER, E.M.; GIERS, G. et al. - Increased frequency of the HLA-DR15 (B1*15011) allele in German patient with self-limited hepatitis C virus infection. Europ. J. clin. Invest., 29: 337-343, 1999.47. LIN, T.M.; CHEN, C.J.; WU, M.M. et al. - Hepatitis B virus markers in Chinese twins. Anticancer Res., 9: 737-741, 1989.48. LONG, K.Z. & SANTOS, J.I. - Vitamins and the regulation of the immune response. Pediat. infect. Dis., 18: 283-290, 1999.49. MANGIA, A.; GENTILE, R.; CASCAVILLA, I. et al. - HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J. Hepat., 30: 984-989, 1999.50. MARTINSON, J.J.; CHAPMAN, N.H.; REES, D.C.; LIU, Y.T. & CLEGG, J.B. - Global distribution of the CCR5 gene 32-basepair deletion. Nature Genet., 16: 100-103, 1997.51. McKIERNAN, S.M.; HAGAN, R.; CURRY, M.; HEGARTY, J.; LAWLOR, E. & KELLEHR, D. - Human leucocyte antigens related to disease outcome in hepatitis C [Abstract]. Hepatology, 28 (suppl): 214A, 1998.52. McKIERNAN, S.M.; HAGAN, R.; CURRY, M. et al. - The MHC is a major determinant of viral status but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology, 118: 1124-1130, 2000.53. MINTON, E.J.; SMILLIE, D.; NEAL, K.R. et al. - Association between MHC class II alleles and clearance of circulating hepatitis C virus. J. infect. Dis., 178: 39-44, 1998.54. MOTA, A.H.; FAINBOIM, H.; TERG, R. & FAINBOIM, L. - Association of chronic active hepatitis and HLA B35 in patients with hepatitis B virus. Tissue Antigens, 30: 238-240, 1987.55. PEANO, G.; MENARDI, G.; PONZETTO, A. & FENOGLIO, L.M. - HLA-DR5 antigen: a genetic factor influencing the outcome of hepatitis C virus infection Arch. intern .Med., 154: 2733-2736, 1994.56. POWELL, E.E.; EDWARDS-SMITH, C.J.; HAY, J.L. et al. - Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 31: 828-833, 2000.57. POWER, J.P.; LAWLOR, E.; DAVIDSON, F. et al. - Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet, 344: 1166-1167, 1994.58. POWER, J.P.; LAWLOR, E.; DAVIDSON, F. et al. - Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet, 345: 1211-1213, 1995.59. POYNARD, T.; BEDOSSA, P. & OPOLON, P. - Nature history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 349: 825-832, 1997.60. RACIOPPI, L.; RONCHESE, F.; SCHWARTZ, R.H. & GERMAIN, R.N. – The molecular basis of class II MHC allelic control of T cell responses. J. Immunol., 147: 3718 – 3727, 1991.61. RENOU, C.; HALFON, P.; POL, S. et al. - Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut, 51: 585-590, 2002.62. SHERON, N.; LAU, J.; DANIELS, H. et al. - Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J. Hepat., 12: 241-245, 1991.63. SMITH, B.C.; GORVE, J.; GUZAIL, M.A. et al. - Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology, 27: 1695-1699, 1998.64. STEEL, C.M.; LUDLAM, C.A.; BEATSON, D. et al. – HLA haplotype A1 B8 DR3 at a risk factor for HIV-related disease. Lancet, 1: 1185-1188, 1988.65. SUMMERFIELD, J.A.; RYDER, S.; SUMIYA, M. et al. - Mannose binding protein gene mutations associated with unusual and severe infection in adults. Lancet, 345: 886-889, 1995.66. TEWS, B.; WILHELM, J.; SUMMERER, D. et al. – Application of the C4’alkylated deoxyribose primer system (CAPS) in allele-specific real-time PCR for increased selectivity in discrimination of single nucleotide sequence variants. Biol. Chem., 384: 1533-1541, 2003.67. THIO, C.L; CARRINGTON, M.; MARTI, D. et al. - Class II HLA alleles and hepatitis B virus persistence in African Americans. J. infect. Dis., 179: 1004-1006, 1999.68. THIO, C.L.; THOMAS, D.L, & CARRINGTON, M. - Chronic viral hepatitis and the human genome. Hepatology, 31: 819-827, 2000.69. THIO, C.L.; THOMAS, D.L.; GOEDERT, J.J. et al. - Racial differences in HLA class II associations with hepatitis C virus outcomes. J. infect. Dis., 184: 16-21, 2001.70. THIO, C.L.; GAO, X.; GOEDERT, J.J. et al. - HLA-Cw*04 and hepatitis C virus persistence. J. Virol., 76: 4792-4797, 2002.71. THIO, C.L.; THOMAS, D.L.; KARACKI, P. et al. - Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J. Virol., 77: 12083- 12087, 2003.72. THOMAS, H.C.; FOSTER, G.R.; SUMIYA, M. et al. - Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet, 348: 1417-1419, 1996.73. THURSZ, M.R.; KWIATKOWSKI, D.; ALLSOPP, C.E.M. et al. - Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. New Engl. J. Med., 332: 1065-1069, 1995.74. TIBBS, C.; DONALDSON, P.; UNDERHILL, J.A. et al. - Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in Northern European Caucasoids. Hepatology, 24: 1342-1345, 1996.75. TILLMANN, H.L.; CHEN, D.F.; TRAUTWEIN, C. et al. - Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut, 48: 714-718, 2001.76. TURNER, D.M.; WILLIAMS, D.M.; SANKARAN, D. et al. - An investigation of polymorphism in the interleukin-10 gene promoter. Europ. J. Immunogenet., 24: 1-8, 1997.77. VAN HATTUM, J.; SCHREUDER, G.M. & SCHALM, S.W. – HLA antigens in patients with various courses after hepatitis B virus infection. Hepatology, 7: 11-14, 1987.78. VERDON, R.; POL, S.; LANDAIS, P. et al. - Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialized patients. J. Hepat., 21: 388-393, 1994.79. VILLANO, S.A.; VLAHOV, D.; NELSON, K.E. et al. - Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology, 29: 908-914, 1999.80. WANG, S.C.; OHATA, M.; SCHRUM, L.; RIPPE, R.A. & TSUKAMOTO, H. - Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J. biol. Chem., 273: 302-308, 1998.81. WILSON, A.G.; DE VRIES, N.; PACIOT, F. et al. - An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA-A1, B8 and DR3 alleles. J. exp. Med., 177: 557-560, 1993.82. WILSON, A.G.; DI GIOVINE, F.S.; BLAKEMORE, A.I. & DUFF, G.W. - Single base polymorphism in the human tumour necrosis factor alpha (TNF-alpha) gene detectable by Ncol restriction of PCR product. Hum. Molec. Genet., 1: 353, 1992.83. YENIGUN, A. & DURUPINAR, B. - Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J. Virol., 76: 1787-1789, 2002.84. YOSHIZAWA, K.; OTA, M.; SAITO, S. et al. - Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease. Tissue Antigens, 61: 159-165, 2003.85. ZAVAGLIA, C.; BORTOLON, C.; FERRIOLI, G et al. – HLA typing in chronic type B, D and C hepatitis. J. Hepat., 24: 658-665, 1996. |
